Figure 1. CAR-T cells versus the solid tumor microenvironment (from Foeng et al 2022). ____________ It is now no secret that chimeric antigen receptor (CAR)-T cell therapy has produced remarkable
"We can now conclude that CAR-T cells can actually cure patients" – Carl June, pioneering CAR-T scientist. Excerpts from the Endpoints article: "A decade after the first-ever patients were infused
Emma Thompson is a PhD candidate in Professor Claudine Bonder's Vascular Biology & Cell Trafficking Laboratory at UniSA's Centre for Cancer Biology. Emma's research is focused on testing Carina Biotech's LGR5-targeting CAR-T
Dr Deborah Rathjen After completing its first (and second) commercial deals in the middle of last year, Carina is now rapidly transitioning from CAR-T discovery company to an emerging clinical
"A NEW AND UNIQUE WAY TO TREAT CANCER, CAR-T THERAPY IS POISED TO TRANSFORM THE OUTLOOK FOR CHILDREN AND ADULTS WITH CERTAIN OTHERWISE INCURABLE CANCERS." Chimeric Antigen Receptor
“THESE CHIMERIC GENES HOLD PROMISE FOR THE IMMUNOTHERAPY OF CANCER." - Dr Zelig Eshhar 1989 CAR-T therapy is a revolutionary new cancer treatment option but its development has been
CHIMERIC ANTIGEN RECEPTORS (CARs) ARE HUMAN-MADE MOLECULES EXPRESSED ON THE SURFACE OF T CELLS, KEY CELLS OF THE IMMUNE SYSTEM These CARs are targeted at markers on cancer cells. T
